(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 13.53% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.91%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.87%.
Esperion Therapeutics's revenue in 2025 is $268,125,000.On average, 3 Wall Street analysts forecast ESPR's revenue for 2025 to be $70,998,655,104, with the lowest ESPR revenue forecast at $65,116,107,562, and the highest ESPR revenue forecast at $77,715,517,896. On average, 3 Wall Street analysts forecast ESPR's revenue for 2026 to be $70,005,461,068, with the lowest ESPR revenue forecast at $61,115,910,714, and the highest ESPR revenue forecast at $80,003,936,960.
In 2027, ESPR is forecast to generate $81,130,202,060 in revenue, with the lowest revenue forecast at $74,558,104,457 and the highest revenue forecast at $91,940,008,200.